HCV & Substance Misuse

Post-HCV Treatment Follow-up and Reinfection

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • Other: 0.75
    • CPHCE: 1.00
  • Cost: Free
  • Release: Sep 6, 2019
  • Expires: Sep 5, 2022
  • Estimated Time to Complete:
    45 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Takako S.  Schaninger Takako S. Schaninger, MD
Associate Professor, Medicine
University of Kentucky College of Medicine
Hospital Epidemiologist
VAMC
Lexington, Kentucky

Needs Statement

Virologic cure of hepatitis C does not mean a cure of advanced liver disease. Ongoing evaluation and management of liver disease is indicated for cirrhotic patients after achieving SVR. Non-hepatologist HCV care providers are not familiar with management of cirrhosis.

This module will increase knowledge of appropriate screening to prevent liver complications post SVR.

This activity has been approved by the KBML as meeting the statutory requirements of HB1

Target Audience

Health care providers making clinical decisions regarding screening methods.

Objectives

Upon completion of this education activity, participants will be able to:

  • Describe the benefits of SVR
  • Describe the screening strategies for HCC and esophageal varices
  • Evaluate patients at high risk for HCV reinfection

Accreditation

CME
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1.

ACGME Competencies

  • Patient care
  • Medical knowledge

Other
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

CPHCE
University of Kentucky College of Public Health certifies that this educational activity was designated for 1.00 hour of Public Health Continuing Education (CPHCE) credit. This course is approved for continuing education by the University of Kentucky College of Public Health. ()

Faculty Disclosure

No speaker or planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

In collaboration with Kentucky Aids Education Training Center and Kentucky Injury Prevention and Research Center University of Kentucky College of Public Health.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.